URS and FDS Authoring

URS and FDS authoring services for pharmaceutical GxP systems. The URS defines what the user needs; the FDS defines how the system meets those needs.

URS structure and content

A well-structured URS covers the user roles, business processes, regulatory requirements, data flows, interfaces, security, audit trail, reports, and operational requirements.

FDS structure and content

The FDS maps each URS requirement to a system function, configuration, or behavior. The FDS covers the functional behavior, performance, interfaces, data validation, error handling, and security.

Traceability matrix

A bidirectional traceability matrix links URS to FDS to test cases to test results. The matrix is maintained through the validation lifecycle.

Authoring approach

The URS is authored from stakeholder interviews, regulatory requirements, and the intended use. The FDS is authored from the URS plus the system design.

How to use this page

Use this URS and FDS Authoring page as a planning checkpoint before vendor selection, architecture review, validation scoping or implementation sequencing. The strongest next step is to compare the guidance with your current SOPs, system inventory, batch records, data flows and QA review routines so the discussion starts from evidence instead of assumptions.

Evidence to prepare

For URS and FDS Authoring, prepare the records, owners, risks and decision criteria linked to urs structure and content, fds structure and content, traceability matrix, authoring approach. Useful evidence includes current process maps, interface lists, audit trail expectations, exception workflows, data retention rules and the business reason for changing the current operating model.

Frequently asked questions

How long does URS and FDS authoring take?

For a typical MES or historian project, URS takes 2-4 weeks, FDS takes 4-8 weeks.

Can the URS be used for vendor selection?

Yes. A well-structured URS is the basis for vendor proposal evaluation, vendor demos, and the vendor selection decision.